Kingdon Capital Management, L.L.C. Aerie Pharmaceuticals Inc Transaction History

Kingdon Capital Management, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$9.12 - $14.49 $7.7 Million - $12.2 Million	-843,940 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$10.46 - $14.46 $3.35 Million - $4.63 Million	-320,403 Reduced 27.52%	843,940 $9.93 Million
Q1 2020 May 15, 2020	SELL	$11.84 - $25.52 $716,106 - $1.54 Million	-60,482 Reduced 4.94%	1,164,343 $15.7 Million
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $7.34 Million - $10.4 Million	414,337 Added 51.12%	1,224,825 $29.6 Million
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $14.9 Million - $22.7 Million	810,488 New	810,488 $15.6 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.